Nucleic Acid Therapeutics Market Size, Share, Growth Analysis, By Technology(Anti-sense and Anti-gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs), By Application(Monogenetic Disorders, Thalassemia, Sickle Cell Anemia, Hemophilia), By Surgery(Hospitals and Academic & Research Institutes), By Region - Industry Forecast 2024-2031

Drivers

Rising Advancements in Molecular Technologies

• Advances in molecular technologies and ongoing research on omics have led many companies to invest heavily in it. The nucleic acid-based therapeutics market is highly competitive and market share is gained through multiple business strategies. Acquisitions, partnerships or collaborations are key sources of revenue in the marketplace. For example, in August 2022, Merck & Co. will launch a $1. announced a new therapeutic RNA collaboration with Orna Therapeutics. This collaboration includes the discovery, development and commercialization of novel RNA-based therapies for vaccines, infectious diseases, and oncology programs.

Rise in the Chronic Diseases

• Increasing investment in nucleic acid therapeutics due to high prevalence of chronic diseases, genetic and others is expected to boost market growth for example, in March 2023, Switch Therapeutics acquired $52 million in a Series, a funding round co-led by Insight Partners and UCB Ventures. The company used these funds to select and promote siRNA therapies for therapeutic neurological disorders and advance its RNAi technology market players invest in nucleic acid-based therapeutics R&D to expand products in the nucleic acid-based in therapy. For example, in January 2023, Agilent Technologies Inc. will have 100,000 shares. invested $725 million in nucleic acid products. The investment will double the production capacity for active pharmaceutical ingredients (API).

Restraints

Delivery Challenges

• Successful delivery of nucleic acid therapies to target cells remains a major hurdle. Ensuring that therapeutic agents reach the target tissue or cells while avoiding off-target effects can be challenging.

Immunodeficiency

• Nucleic acid therapy can activate the immune system, which can lead to adverse or decreased side effects. Immunosuppressive strategies are essential for the success of these therapies.

Safety Issues

• The long-term safety of nucleic acid therapies, especially gene therapy, is a concern. The possibility of unintended consequences, such as insertion mutagenesis or delayed immune responses, needs to be carefully investigated and addressed.